Navigation Links
Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
Date:4/8/2013

NEW YORK, April 8, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.  The abstract is titled "Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma multiforme) patients." It will be presented during Poster Session 47 from 1 to 5 p.m. EDT on April 8 by Johan Skog , Ph.D., the newly appointed chief scientific officer of Exosome Diagnostics.   

In this study, Exosome Diagnostics used its proprietary RNA-extraction technology to measure a broad spectrum of full-length mRNA and microRNA from low volumes (2 mL) of frozen, archival serum from brain cancer patients enrolled in a therapeutic clinical trial.  Prior to the introduction of Exosome Diagnostics' technology, similar biomarker analysis would have required performing invasive brain tissue biopsies.

This clinical study represents the third biofluid in which Exosome Diagnostics has demonstrated the ability to harvest disease-specific RNA biomarkers.  Data have been presented in clinical studies from different disease groups from urine, blood, and cerebrospinal fluid exosome preparations.

"Extraction of high-quality RNA, particularly intact messenger RNA, from blood, urine or CSF samples is an important advance for discovering and measuring both known and novel biomarkers for patient selection and drug response," said Johan Skog , Ph.D.  "This study demonstrates that frozen and archived biofluid samples can be interrogated for gene expression along with fresh samples in patient populations of interest to clinical investigators and drug developers."

James McCullough , chief executive officer of Exosome said, "Rapid, reproducible extraction of high quality RNA with appropriate internal quality control from frozen blood samples satisfies an important request from our pharmaceutical partners to unlock the potential of their vast clinical trial bio-banks.  We are now firming plans to launch an Exosome Diagnostics life sciences kit product line in early 2014 to enable drug developers and researchers to pursue biomarker discovery in cancer, CNS and other diseases."   

Exosomes are microscopic packages shed by all cells into biofluids such as blood, urine and cerebrospinal fluid.  Exosomes protect an abundance of active genetic material (ribonucleic acid or "RNA") that, when properly harvested, can produce accurate molecular diagnostic measurements using standard PCR and sequencing instruments.  In addition to its planned life science product line, Exosome Diagnostics has been conducing multi-center clinical validation studies in partnership with the Prostate Cancer Foundation for the first-ever regulated exosome in vitro diagnostic, which targets early stage prostate cancer from a random patient urine sample. 

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is developing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. For more information, please visit www.exosomedx.com.


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
2. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
3. Cardium Presents Year-End 2012 Financial Results And Recent Developments
4. Pharmagen Presents to North Carolina General Assembly at N.C. Bios Legislative Breakfast
5. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
6. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
7. Versus Presents New Hand-Hygiene Alliance, Wireless Sensors and RTLS Education at HIMSS13
8. University Hospitals Case Medical Center Presents Study On The Elimination Of Retained Surgical Sponges
9. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
10. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
11. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Avril 2016   ... +5% sur le trimestre, soutenu par une croissance ... Croissance de +16% des ventes aux hôpitaux ... Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur ... aujourd,hui son chiffre d,affaires pour le premier trimestre ...
(Date:4/27/2016)... Tie-up with Government hospitals as ... to save newborns   Fortis La Femme, ... collaboration with Breast Milk Foundation (BMF), a non-profit organization within ... Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes that ... and should be available to babies deprived of mother,s milk.  ...
(Date:4/27/2016)... , April 27, 2016 ... USD 2.14 billion by 2022, according to a ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... affecting the efficiency and accuracy delivered by the ... demand for novel urinalysis instruments and consumables. For ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... Grants Pass, OR (PRWEB) , ... April 29, 2016 , ... ... nutritionists suggest dinner as the meal to miss. That was among the many new ... True Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... media enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, ... as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors ...
Breaking Medicine News(10 mins):